Skip to main content
Log in

Praxisnahe menopausale Hormontherapie

Practical menopausal hormone therapy

  • Originalien
  • Published:
Journal für Mineralstoffwechsel & Muskuloskelettale Erkrankungen Aims and scope

Zusammenfassung

Mit steigender Lebenserwartung verbringen heute Frauen ein Drittel ihres Lebens und darüber hinaus in der Menopause. Die überwiegende Mehrheit leidet unter Symptomen, die sich negativ auf ihre Lebensqualität auswirken. Systemische vasomotorische Symptome (VMS) wie Hitzewallungen und Schweißausbrüche sind die klassische Symptomgruppe, die 80 % der peri- und postmenopausalen Frauen betrifft. Lokale vulvovaginale und harnableitende Symptome, die heute als genitourinäres Syndrom der Menopause (GSM) bezeichnet werden, treten bei etwa der Hälfte der postmenopausalen Frauen auf. Östrogen ist nach wie vor die wirksamste Behandlung für diverse klimakterische Beschwerden. Bei Frauen mit erhöhtem Frakturrisiko kann es zur Osteoporoseprävention verwendet werden. Für Frauen, die eine vorzeitige Menopause erleben, sei es aufgrund einer primären Ovarialinsuffizienz (POI) oder anderer Ätiologien, ist Östrogen die natürlichste Substanz zur Linderung von Beschwerden und kann auch zur Prävention chronischer Krankheiten eingesetzt werden. Die seit der WHI-Studie in Verruf geratene menopausale Hormontherapie (MHT) ist heute in einem völlig neuen Licht zu sehen, nicht nur aufgrund neuer Studiendaten und Erkenntnisse, sondern auch aufgrund verbesserter Anwendungsformen der hormonellen Komponenten. Die für viele Frauen im Klimakterium so wichtige Hormontherapie wurde in den letzten Jahren sträflich vernachlässigt und soll hier aus der Sicht eines langjährigen Praktikers beleuchtet werden.

Abstract

Today, with increasing life expectancy, women spend a third of their lives or more in menopause. The vast majority have symptoms that negatively impact their quality of life. Systemic vasomotor symptoms (VMSs) like hot flushes and attacks of sweating are the classic group of symptoms that affect 80% of peri- and postmenopausal women. Local vulvovaginal and urinary tract symptoms, now known as genitourinary syndrome of menopause (GSM), occur in half of postmenopausal women. Estrogen is still the most effective treatment for various menopausal symptoms. It can be used to prevent osteoporosis in women with high fracture risk. For women who experience premature menopause, be it due to primary ovarian insufficiency (POI) or iatrogenic aetiologies, estrogen is the most natural substance for relief of symptoms and prevention of chronic diseases. Menopausal hormone therapy (MHT), which has fallen into disrepute since the WHI study, can now be seen in a completely new light, not only because of new study data and findings but also because of the different ways in which the hormonal components are used. Hormonal treatment during menopause, which is so important for many women, has been criminally neglected in recent years and is to be examined in the following article from the perspective of a long-term practitioner.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Literatur

  1. North American Menopause Society, March 2021 https://www.menopause.org/, (2014) Menopause practice: a clinician’s guide

  2. Murphy SL, Xu J, Kockanek KD (2013) Deaths: final data for 2010. Natl Vital Stat Rep 61(4):1–117

    PubMed  Google Scholar 

  3. Rossouw JE, Anderson GL, Prentice RL et al (2002) Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333

    Article  CAS  Google Scholar 

  4. L’Hermite M (2013) HRT optimization using transdermal estradiol plus micronized progesterone, a safer HRT. Climacteric 6(1):44–53

    Article  Google Scholar 

  5. Vinogradova Y, Coupland C, Hippisley-Cox J (2019) Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ 364:k4810

    Article  Google Scholar 

  6. AWMF-S3-Leitlinien Peri- und Postmenopause, Stand 2020

  7. Gompel A (2012) Micronized progesterone and its impact on the endometrium and breast vs. progestogens. Climacteric 15(1):18–25

    Article  CAS  Google Scholar 

  8. Clarkson TB, Melendez GC, Appt SE (2013) Timing hypothesis for postmenopausal hormone therapy: its origin, current status, and future. Menopause 20(3):342–353

    Article  Google Scholar 

  9. Clarkson TB, Mehaffey M (2009) Coronary heart disease of females: lessons learned from nonhuman primates. Am J Primatol 71:785–793

    Article  Google Scholar 

  10. Pinkerton JV, Aguirre FS, Blake J, Hodis H et al (2017) The 2017 hormone therapy position statement of the North American Menopause Society. Menopause 24(7):728–753

    Article  Google Scholar 

  11. Sturdee DW, Hunter MS, Maki PM et al (2017) The menopausal hot flush: a review. Climacteric 20(4):296–305

    Article  CAS  Google Scholar 

  12. Thurston RC (2018) Vasomotor symptoms: natural history, physiology, and links with cardiovascular health. Climacteric 21(2):96–100

    Article  CAS  Google Scholar 

  13. Maclennan AH, Broadbent JL, Lester S, Moore V (2004) Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 4:CD2978

    Google Scholar 

  14. Khosla S, Oursler MJ, Monroe DG (2012) Estrogen and the skeleton. Trends Endocrinol Metab 23(11):576–581

    Article  CAS  Google Scholar 

  15. Nappi RE, Palacios S, Particco M, Panay N (2016) The REVIVE (real women’s views of treatment options for menopausal vaginal changes) survey in Europe: country-specific comparisons of postmenopausal women’s perceptions, experiences, and needs. Maturitas 91:81–90

    Article  Google Scholar 

  16. Nappi RE, Palacios S, Bruyniks N et al (2019) The burden of vulvovaginal atrophy on women’s daily living: implications on quality of life from a face-to-face real-life survey. Menopause 26(5):485–491

    Article  Google Scholar 

  17. Rahn DD, Carberry C, Sanses TV et al (2015) Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstet Gynecol 124:1147–1156

    Article  Google Scholar 

  18. Sullivan SD, Sarrel PM, Nelson LM (2016) Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause. Fertil Steril 106(7):1588–1599

    Article  CAS  Google Scholar 

  19. Langer RD, Simon JA, Pines A, Lobo RA, Hodis HN, Pickar JH, Archer DF, Sarrel PM, Utian WH (2017) Menopausal hormone therapy for primary prevention: why the USPSTF is wrong. Menopause 24(10):1101–1112

    Article  Google Scholar 

  20. Baber RJ, Panay N, Fenton A, the IMS Writing Group (2016) 2016 IMS recommendations on women’s midlife health and menopause hormone therapy. Climacteric 19(2):109–150

    Article  CAS  Google Scholar 

  21. Lobo R, Davis S, De Villiers T et al (2014) Prevention of diseases after menopause. Climacteric 17:540–556

    Article  CAS  Google Scholar 

  22. Sattar N, Preiss D, Murray HM et al (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials. Lancet 375:725–742

    Google Scholar 

  23. Langer RD (2017) The evidence base for HRT: what can we believe. Climacteric 20:91–96

    Article  CAS  Google Scholar 

  24. Kaunitz A, Manson J (2015) Management of menopausal symptoms. Obstet Gynecol 126(4):859–876

    Article  Google Scholar 

  25. Chen W, Rosner B, Hankinson SE, Colditz GA, Willett WC (2011) Moderate alcohol consumption during adult life, drinking patterns, and breast cancer risk. JAMA 306:1184–1890

    Google Scholar 

  26. Gordon JL, Rubinow DR, Eisenlohr-Moul TA, Xia K, Schmidt PJ, Girdler S (2018) Efficacy of Transdermal Estradiol and Micronized Progesterone in the Prevention of Depressive Symptoms in the Menopause Transition: A Randomized Clinical Trial. JAMA Psychiatry 75(2):149–157

  27. Hodis HN, Mack WJ (2018) Cardiovascular risk after withdrawal of hormone therapy. Menopause 25(4):365–367

    Article  Google Scholar 

  28. Hodis HN, Mack WJ, Henderson VW et al (2016) Vascular effects of early versus late postmenopausal treatment with estradiol. N Eng J Med 374(13):1221–1231

    Article  CAS  Google Scholar 

  29. Stuenkel C, Davis SR, Gompel A et al (2015) Treatment of symptoms of the menopause: an Endocrine Society Clinical Practice guideline. J Clin Endocrinol Metab 100:3975–4011

    Article  CAS  Google Scholar 

  30. Maas AHEM, Rosano G, Cifkova R, Chieffo A, van Dijken D, Hamoda H, Kunadian V, Laan E, Lambrinoudaki I, Maclaran K, Panay N, Stevenson JC, van Trotsenburg M, Collins P (2021) Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists. Eur Heart J 42(10):967–984

    Article  Google Scholar 

  31. Paciuc J (2020) Hormone Therapy in Menopause. Adv Exp Med Biol 1242:89–120. https://doi.org/10.1007/978-3-030-38474-6_6. PMID: 32406030

    Article  CAS  PubMed  Google Scholar 

  32. Lobo R (2017) Hormone-replacement therapy: current thinking. Nat Rev Endocrinol 13:220

    Article  CAS  Google Scholar 

  33. Chester RC, Kling JM, Manson JE (2018) What the Women’s Health Initiative has taught us about menopausal hormone therapy. Clin Cardiol 41(2):247–252

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Bernhard Svejda.

Ethics declarations

Interessenkonflikt

B. Svejda gibt an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

Hinweis des Verlags

Der Verlag bleibt in Hinblick auf geografische Zuordnungen und Gebietsbezeichnungen in veröffentlichten Karten und Institutsadressen neutral.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Svejda, B. Praxisnahe menopausale Hormontherapie. J. Miner. Stoffwechs. Muskuloskelet. Erkrank. 28, 47–55 (2021). https://doi.org/10.1007/s41970-021-00153-x

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s41970-021-00153-x

Schlüsselwörter

Keywords

Navigation